<DOC>
	<DOCNO>NCT00613067</DOCNO>
	<brief_summary>Amplitude change N1 N1/P2 ERP component response different tone intensity suggest correlative central serotonergic activity . A strong loudness dependence amplitude increase ( strong intensity dependence ) reflect low serotonergic neurotransmission vice versa . Many researcher assume brain serotonergic activity could influence treatment response highly selective serotonin reuptake inhibitor depression anxiety disorder . There couple study report association N1 amplitude intensity dependence response Citalopram ( positive correlation ) Reboxetine ( negative correlation ) treatment major depressive disorder patient . But far report association ERP N1 antidepressant response GAD patient . So , would interest explore correlation ERP N1 amplitude change Escitalopram treatment responsiveness GAD patient .</brief_summary>
	<brief_title>ERP N1 Treatment Predictor Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>DSMIV TR GAD Hamilton Rating Scale Anxiety ( HAMA ) &gt; 18 18 75 year old Severe medical illness Other psychiatric illness HAMD &gt; 18 High suicidal risk pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Generalized anxiety disorder</keyword>
	<keyword>N100</keyword>
	<keyword>Central serotonergic activity</keyword>
</DOC>